MGO One Seven LLC Has $254,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN

MGO One Seven LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 483 shares of the biopharmaceutical company’s stock after purchasing an additional 106 shares during the period. MGO One Seven LLC’s holdings in Regeneron Pharmaceuticals were worth $254,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. GW Henssler & Associates Ltd. grew its position in shares of Regeneron Pharmaceuticals by 5.5% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 21,482 shares of the biopharmaceutical company’s stock worth $11,278,000 after purchasing an additional 1,122 shares in the last quarter. Meritage Portfolio Management acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $6,014,000. CWM LLC boosted its position in shares of Regeneron Pharmaceuticals by 770.0% during the 2nd quarter. CWM LLC now owns 35,506 shares of the biopharmaceutical company’s stock worth $18,641,000 after acquiring an additional 31,425 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 7.9% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 10,853 shares of the biopharmaceutical company’s stock worth $5,699,000 after acquiring an additional 792 shares in the last quarter. Finally, Concurrent Investment Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 136.4% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,622 shares of the biopharmaceutical company’s stock worth $852,000 after acquiring an additional 936 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on REGN shares. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a research report on Friday, August 1st. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 14th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $817.88.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $578.05 on Monday. The company has a fifty day moving average price of $574.64 and a 200-day moving average price of $562.12. The company has a market capitalization of $61.27 billion, a P/E ratio of 14.57, a PEG ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,002.69. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the firm earned $11.56 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.